A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 18
- Population
- ALL · 50 Years
- Duration
- 2020-05-28 to 2021-05-08
- Intervention
- IBI302 (the first dose level); IBI302 (the second dose level); Aflibercept
- Comparator
- 2mg aflibercept
- Outcomes measured
- Ocular safety, assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photography — Baseline to Day140; Incidence of adverse events — Baseline to Day140; Changes in central subfield thickness by OCT compared with baseline — Baseline to Day140; Changes in CNV characteristics and CNV area by FA compared with baseline — Baseline to Day140; Changes in BCVA compared with baseline — Baseline to Day140; Positive rate of anti-drug antibody and neutralizing antibody of IBI302 — Baseline to Day140; the area under the drug-time curve from 0 to time t of IBI302 — Baseline to Day140; the area under the curve at the time of 0-infinity of IBI302 — Baseline to Day140; The peak concentration of IBI302 — Baseline to Day140; The peak time of IBI302 — Baseline to Day140; Clearance rate of IBI302 — Baseline to Day140; Half-life of IBI302 — Baseline to Day140; VEGF concentration — Baseline to Day140; Concentration of complement fragments — Baseline to Day140
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.